Alpha-lipoic acid occupies an unusual spot in the supplement aisle. It is not a vitamin, since the body makes its own. It is not an herb. It has a legitimate biochemical job inside the mitochondria, a plausible antioxidant story, and a research record stretching back to the 1990s that includes real controlled trials rather than just marketing. It is also a good example of a compound whose reputation was built on one delivery method (an IV drip) and then transferred, somewhat loosely, to another (a capsule).
Here is what the research actually supports, where the evidence thins out, and how to use it sensibly if you decide to.
What Alpha-Lipoic Acid Is
Alpha-lipoic acid, usually shortened to ALA (not to be confused with alpha-linolenic acid, the plant omega-3 that shares the abbreviation), is a sulfur-containing compound the body synthesizes in small amounts. Its day job is as a cofactor for two enzyme complexes at the heart of energy metabolism, the ones that convert pyruvate and alpha-ketoglutarate into forms the mitochondria can burn. Without it, glucose cannot be fully turned into ATP.
At supplemental doses far above what the body makes, ALA does something different. It circulates as a free antioxidant that is unusual in being both water- and fat-soluble, so it can act in cell membranes and in the watery interior alike. It also appears to help recycle other antioxidants, including glutathione, vitamin C, and vitamin E, back into their active forms, and to chelate certain metals. This dual solubility and recycling role is the basis of most of the claims made for it. Our antioxidants guide explains why “antioxidant” on its own is a weak reason to take anything; the question is always what happens in trials.
Supplements come in two flavors. Racemic ALA is a 50/50 mix of the natural R-form and the synthetic S-form, and it is what nearly all published trials used. R-ALA is the natural form alone, better absorbed on a milligram basis but less chemically stable and more expensive. When R-ALA is used, doses are often set at about half the racemic equivalent.
Absorption: The Empty-Stomach Rule
ALA is absorbed quickly but incompletely. Roughly 30 percent of an oral dose reaches the bloodstream, plasma levels peak within 30 to 60 minutes, and the half-life is short, under an hour. Taking it with food reduces absorption substantially, which is why trial protocols and most labels specify taking it 30 to 60 minutes before a meal or at least two hours after one.
That short half-life matters when interpreting the research. The intravenous studies that produced the most striking results delivered sustained high blood levels that oral dosing simply does not replicate. Some of the gap between IV and oral outcomes is likely just that.
Evidence Area 1: Nerve-Related Discomfort
Most of ALA’s reputation comes from a series of European trials, many from Germany where it is licensed as a prescription product, in people with tingling, burning, and numbness related to long-standing high blood sugar. The clearest results came from intravenous ALA at 600 mg per day for about three weeks, which produced consistent improvements in symptom scores compared with placebo across several trials.
Oral trials are more mixed. A number of studies using 600 mg per day of oral ALA for four to five weeks reported meaningful reductions in symptom scores, and pooled analyses generally find a benefit over placebo. But longer oral trials have been less consistent, some showing improvement in symptoms without change in objective nerve measures, and some showing no clear advantage. The fair summary is that trials suggest oral ALA may modestly ease these symptoms in some people, that the IV data are stronger, and that in countries where it is used clinically it is a supervised prescription, not a substitute for managing the underlying blood sugar. Anyone with nerve symptoms should be evaluated by a clinician rather than self-treating.
Evidence Area 2: Blood Sugar and Insulin Sensitivity
Given its role in glucose metabolism, ALA has been tested repeatedly for effects on blood sugar. Small trials in people with impaired glucose handling have found modest reductions in fasting glucose and improvements in insulin sensitivity markers, and pooled analyses tend to confirm a small effect. Doses in these studies ranged from 300 to 1,200 mg per day, and trial lengths were typically two to six months.
Two caveats. First, the effect sizes are small, well below what diet, exercise, or medication produce, and not large enough to change what anyone should be doing about their blood sugar. Second, the trials are heterogeneous, with different populations, doses, and durations, which makes the pooled numbers less reliable than they look. For comparison, berberine has a larger and more consistent body of blood sugar research, though it comes with its own interaction issues.
Evidence Area 3: Weight
Several trials, mostly in people with excess weight, have tested ALA for weight change. Pooled analyses of those trials found participants on ALA lost roughly 1 to 1.5 kg more than placebo over periods of eight weeks to about a year, with higher doses (around 1,200 mg per day) showing slightly larger effects. That is a real, statistically supported difference. It is also a small one, and nothing in the data suggests it grows over time or works without the diet and activity changes participants were also making. Anyone selling ALA as a fat burner is stretching a modest finding well past its limits.
Evidence Area 4: Everything Else
ALA appears on labels for skin aging, cognitive support, liver health, athletic recovery, and general “mitochondrial support.” For most of these, the evidence is animal or cell-culture work, single small human trials, or nothing at all. Topical ALA has some small trials for skin appearance. Oral ALA for cognition has preliminary and inconsistent data. The mitochondrial claims rest largely on rodent studies in which very old animals given ALA with acetyl-L-carnitine showed improvements in activity and mitochondrial markers; the human follow-up has been thin. None of this is disqualifying, but none of it justifies confident claims either. Our glutathione guide covers the related question of whether antioxidant supplements raise glutathione meaningfully in people.
Dosing in Practice
- Typical dose: 300 to 600 mg per day of racemic ALA, which is the range used in most trials. Some blood sugar and weight trials went to 1,200 mg per day, usually divided.
- R-ALA: 100 to 300 mg per day, given its better absorption. Look for a stabilized form, since plain R-ALA degrades with heat and time.
- Timing: on an empty stomach, 30 to 60 minutes before eating. If it causes nausea, taking it with a small amount of food is a reasonable compromise at some cost to absorption.
- Spacing from minerals: ALA can bind minerals such as iron and zinc; separating it from mineral supplements by a couple of hours is a sensible precaution.
- Duration: most positive trials ran at least four weeks. There is no evidence that cycling is necessary, but there is also limited data beyond about a year of continuous use.
Safety and Interactions
ALA is well tolerated in trials at the usual doses. The most common complaints are nausea, stomach upset, skin rash, and an odd smell to the urine. A few issues deserve more attention:
- Blood sugar medication. Because ALA can lower glucose, combining it with insulin or oral diabetes drugs raises the possibility of blood sugar dropping too far. Anyone on those medications should involve their prescriber and monitor readings after starting.
- Thyroid hormone. Animal data and limited human reports suggest ALA may reduce conversion of thyroid hormone to its active form. People taking thyroid medication should mention it to their provider and watch for changes in how they feel.
- Insulin autoimmune syndrome. A rare reaction in which the body produces antibodies to its own insulin, causing episodes of very low blood sugar, has been reported in people taking ALA, mostly in East Asian individuals carrying a specific immune gene variant. It resolves on stopping the supplement. It is uncommon, but worth knowing about if you experience unexplained shakiness, sweating, or confusion.
- Thiamine. In animal studies, ALA given to thiamine-deficient animals caused harm. This is a theoretical concern for people with heavy alcohol use or poor diets; ensuring adequate thiamine intake is a reasonable precaution.
- Chemotherapy. Antioxidants can in theory interfere with treatments that rely on oxidative damage. Anyone undergoing cancer treatment should not add ALA without clearing it with their oncology team.
- Pregnancy, nursing, and children. There is not enough safety data to recommend use in these groups.
Bottom Line
Alpha-lipoic acid is a legitimate compound with a real research record, and that record is more honest than most: it shows modest oral benefits for certain nerve symptoms and for blood sugar markers, a small effect on weight, and mostly preliminary data for everything else. The strongest results came from intravenous dosing that a capsule cannot reproduce. If you use it, 300 to 600 mg per day on an empty stomach is the evidence-based range, and the people who most need to check first are those on diabetes or thyroid medication. For more on the compound itself, see our alpha-lipoic acid supplement page.
This article is for educational purposes only and is not medical advice. Talk to a qualified healthcare provider before starting any new supplement, especially if you are pregnant, nursing, taking medication, or managing a health condition.